Most importantly, they showed in vivo that the treatment of S100A9 Tg mice with the anti-PD1 inhibitor significantly improves the colony-forming capacity of the BM cells and increases most of the hematological parameters, further reinforcing the role of this pathway in the ineffective hematopoiesis of MDS. This evidence concerns the gene PDCD1 and myelodysplastic syndrome.